☆ 4.1 Article

Cost-utility of ambrisentan and bosentan for pediatric pulmonary arterial hypertension

EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Pediatrics

Ambrisentan for in pediatric pulmonary arterial hypertension: A cost-utility analysis

Jefferson A. Buendia et al.

Summary: This study aims to determine the cost-utility of ambrisentan compared to sildenafil in treating pediatric patients with pulmonary arterial hypertension. The results showed that ambrisentan was associated with higher costs and higher quality-adjusted life-years (QALYs) compared to sildenafil. Therefore, our economic evaluation concludes that ambrisentan is not cost-effective for treating pediatric patients with pulmonary arterial hypertension in Colombia.

PEDIATRIC PULMONOLOGY (2023)

添加到收藏夹

Article Health Care Sciences & Services

Phosphodiesterase 5 Inhibitor for Pediatric Pulmonary Arterial Hypertension: A Cost-Utility Analysis

Jefferson Antonio Buendia et al.

Summary: This study aims to determine the cost-utility of tadalafil compared to sildenafil in treating pediatric patients with pulmonary arterial hypertension. The results show that although tadalafil is more expensive, it is not more cost-effective than sildenafil. This conclusion should be used by decision-makers to improve clinical practice guidelines.

VALUE IN HEALTH REGIONAL ISSUES (2023)

添加到收藏夹

Article Pediatrics

Safety and tolerability of combination therapy with ambrisentan and tadalafil for the treatment of pulmonary arterial hypertension in children: Real-world experience

Azadeh Issapour et al.

Summary: This study retrospectively observed the safety and tolerability of using ambrisentan and tadalafil in pediatric pulmonary hypertension treatment. The results showed that combination therapy with ambrisentan and tadalafil was well-tolerated and had an acceptable safety profile in children, and was associated with improved exercise capacity and hemodynamics.

PEDIATRIC PULMONOLOGY (2022)

添加到收藏夹

Review Pharmacology & Pharmacy

Comparative assessment of efficacy and safety of ambrisentan and bosentan in patients with pulmonary arterial hypertension: A meta-analysis

Qinhua Zhao et al.

Summary: The network meta-analysis showed that ambrisentan and bosentan had similar efficacy in treating PAH patients, but ambrisentan showed better tolerance in handling abnormal liver function compared to bosentan.

JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Disease characteristics and clinical outcome over two decades from the Swiss pulmonary hypertension registry

Paula Appenzeller et al.

Summary: Pulmonary hypertension, especially pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension, is a rare and progressive condition. This retrospective analysis of the Swiss Pulmonary Hypertension Registry found that newly diagnosed patients are older, have a more balanced gender distribution, improved hemodynamics, and better survival rates.

PULMONARY CIRCULATION (2022)

添加到收藏夹

Article Health Care Sciences & Services

Estimating cost-effectiveness thresholds under a managed healthcare system: experiences from Colombia

Oscar Espinosa et al.

Summary: This study examined the healthcare system of the middle-income country Colombia, estimating the cost-effectiveness threshold and exploring the variation of health expenditures and outcomes. The threshold was found to be around one times the GDP per capita, providing valuable insights for decision-making in a managed healthcare system.

HEALTH POLICY AND PLANNING (2022)

添加到收藏夹

Review Pediatrics

Systematic review and cost-effectiveness of bosentan and sildenafil as therapeutic drugs for pediatric pulmonary arterial hypertension

Tingting Chen et al.

Summary: Through systematic review and economic evaluation research, it was found that sildenafil is a more cost-effective and effective choice for the treatment of PAH in children.

PEDIATRIC PULMONOLOGY (2021)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

Treatment of pulmonary arterial hypertension in children

Matthias Gorenflo et al.

Summary: Treatment of pediatric pulmonary arterial hypertension has advanced significantly, with new drug therapies being evaluated. Special attention is needed for the pharmacology of PAH drugs in children and more research is required.

CARDIOVASCULAR DIAGNOSIS AND THERAPY (2021)

添加到收藏夹

Article Medicine, General & Internal

Children and Adolescents with Pulmonary Arterial Hypertension: Baseline and Follow-Up Data from the Polish Registry of Pulmonary Hypertension (BNP-PL)

Joanna Kwiatkowska et al.

JOURNAL OF CLINICAL MEDICINE (2020)

添加到收藏夹

Editorial Material Cardiac & Cardiovascular Systems

2019 updated consensus statement on the diagnosis and treatment of pediatric pulmonary hypertension: The European Pediatric Pulmonary Vascular Disease Network (EPPVDN), endorsed by AEPC, ESPR and ISHLT

Georg Hansmann et al.

JOURNAL OF HEART AND LUNG TRANSPLANTATION (2019)

添加到收藏夹

Article Respiratory System

Paediatric pulmonary arterial hypertension: updates on definition, classification, diagnostics and management

Erika B. Rosenzweig et al.

EUROPEAN RESPIRATORY JOURNAL (2019)

添加到收藏夹

Review Respiratory System

Cost Effectiveness of Bosentan for Pulmonary Arterial Hypertension: A Systematic Review

Ruxu You et al.

CANADIAN RESPIRATORY JOURNAL (2018)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

Pulmonary Hypertension in Infants, Children, and Young Adults

Georg Hansmann

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)

添加到收藏夹

Article Critical Care Medicine

Efficacy and Safety of Pulmonary Arterial Hypertension-specific Therapy in Pulmonary Arterial Hypertension A Meta-analysis of Randomized Controlled Trials

Huan-long Liu et al.

CHEST (2016)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

FUTURE-2: Results from an open-label, long-term safety and tolerability extension study using the pediatric FormUlation of bosenTan in pUlmonary arterial hypeRtEnsion

Rolf M. F. Berger et al.

INTERNATIONAL JOURNAL OF CARDIOLOGY (2016)

添加到收藏夹

Article Economics

Cost Effectiveness of First-Line Oral Therapies for Pulmonary Arterial Hypertension: A Modelling Study

Kathryn Coyle et al.

PHARMACOECONOMICS (2016)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

STARTS-2 Long-Term Survival With Oral Sildenafil Monotherapy in Treatment- Naive Pediatric Pulmonary Arterial Hypertension

Robyn J. Barst et al.

CIRCULATION (2014)

添加到收藏夹

Review Pediatrics

Drug Treatment of Pulmonary Hypertension in Children

Erika E. Vorhies et al.

PEDIATRIC DRUGS (2014)

添加到收藏夹

Article Pediatrics

Clinical Safety, Pharmacokinetics, and Efficacy of Ambrisentan Therapy in Children With Pulmonary Arterial Hypertension

Shinichi Takatsuki et al.

PEDIATRIC PULMONOLOGY (2013)

添加到收藏夹

Article Economics

Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement

Don Husereau et al.

VALUE IN HEALTH (2013)

添加到收藏夹

Review Respiratory System

Understanding the impact of pulmonary arterial hypertension on patients' and carers' lives

Loic Guillevin et al.

EUROPEAN RESPIRATORY REVIEW (2013)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Survival in Childhood Pulmonary Arterial Hypertension Insights From the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management

Robyn J. Barst et al.

CIRCULATION (2012)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Ambrisentan for the treatment of pulmonary arterial hypertension -: Results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) Study 1 and 2

Nazzareno Galie et al.

CIRCULATION (2008)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Quality of life in pulmonary arterial hypertension: Improvement and maintenance with bosentan

Anne M. Keogh et al.

JOURNAL OF HEART AND LUNG TRANSPLANTATION (2007)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.